CT guided percutaneous transhepatic microwave ablation for primary liver cancer in segment 9
10.3760/cma.j.cn113884-20200415-00199
- VernacularTitle:CT引导下经皮肝穿刺微波消融治疗Ⅸ段原发性肝癌的临床研究
- Author:
Zaiguo WANG
1
;
Weibiao ZHANG
;
Zhenwei YE
;
Yan HUANG
;
Zhenwen HOU
;
Yanxia MO
;
Jingzhu JIANG
;
Dehui HUANG
;
Xiaohong HUANG
;
Zhiqiang LIN
;
Ailing ZHANG
Author Information
1. 南方医科大学附属东莞人民医院肝胆胰脾外科，东莞 523059
- From:
Chinese Journal of Hepatobiliary Surgery
2020;26(11):825-828
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the efficacy and safety of CT guided percutaneous transhepatic microwave ablation (PTPMWA) for primary liver cancer (PLC) in liver segment 9.Methods:A retrospective study was conducted on PLC patients between October 2013 and March 2019 at Dongguan People’s Hospital, Southern Medical University. Of 41 patients who entered into the study, there were 36 males and 5 females, with an average age of 59.1 years. These patients were diagnosed to have PLC in segment 9. The surgical related data and follow-up results were collected and analyzed.Results:All patients enrolled in the study completed the treatment procedure. CT scan was performed immediately after ablation which showed that the tumor areas to be completely covered by ablation. The duration of operation ranged from 45 to 260 (mean 91) min. The amount of bleeding during treatment was 1.0 to 5.0 (mean 1.4) ml. The complete response rate was 97.6% (40 patients) and the partial response rate was 2.4% (1 patient). The cumulative survival rates at 1, 2, 3, 4 and 5 years were 95.1%, 85.4%, 75.3%, 45.2% and 45.2%, respectively. Only 4 patients (9.8%) developed recurrence after treatment. The timings of recurrence were 1, 6, 13 and 67 months after treatment, respectively. The recurrent lesions were ablated again and complete response was obtained in all patients. There were no serious problems related to complications from ablation. The rate of postoperative complication was 7.3% (3 patients).Conclusion:PTPMWA is a novel treatment for patients with PLC in liver segment 9, the advantages of this treatment include good safety, high efficacy, low complications and local recurrence. The treatment is worthy of further future studies.
